1. Response to the ASHM 2023 statement on the use of doxy‐PEP in Australia: considerations and recommendations.
- Author
-
Bell, Sara F E, Sweeney, Emma L, Kong, Fabian Y S, Whiley, David M, Bradshaw, Catriona S, and Tickner, Jacob A
- Abstract
The article discusses the 2023 Consensus statement on doxycycline prophylaxis (doxy-PEP) for the prevention of syphilis, chlamydia, and gonorrhea among gay, bisexual, and other men who have sex with men (GBMSM) in Australia. It highlights the potential benefits of doxy-PEP in reducing syphilis incidence but raises concerns about increasing antimicrobial resistance (AMR) and the need for effective monitoring of doxy-PEP use. The article compares doxy-PEP to HIV pre-exposure prophylaxis (PrEP) and emphasizes the differences in effectiveness and potential risks. It also discusses the impact of doxy-PEP on antimicrobial stewardship, resistance, and the microbiome. The article concludes by suggesting that caution should be exercised in supporting and implementing doxy-PEP and recommends comprehensive counseling and antimicrobial stewardship programs. The text discusses opportunities to enhance surveillance of sexually transmitted infections (STIs), antimicrobial resistance (AMR), and antimicrobial use. The authors support nine recommendations for research, guidelines, and policy, including the need for adequate funding and monitoring of AMR. They suggest implementing standardized data collection methods and interoperable systems to improve understanding of the drivers of resistance. The authors also emphasize the importance of access to STI testing, including AMR testing, and the need for comprehensive surveillance systems to monitor the impact of doxy-PEP use. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF